I attended the Synairgen AGM last Friday (June 22nd 2018), which was held at the offices of Fladgate LLP, 16 Great Queen Street, London. For investors who is unfamiliar with the company, Synairgen is an AIM listed UK based biotech company focused primarily on developing new treatments for Asthma, COPD and other respiratory diseases. The company floated on AIM in November 2004, issuing approximately 8m shares at 130p/share valuing the company at around £28m. There have been several placings since the IPO and the shares now trade at around 13.5p/share valuing Synairgen at about £12.5m. The company broker Finncap raised their price target from 35p to 63p/share on Friday following an update on the clinical progress of their lead asset, SNG001 (beta-interferon). Despite the upgrade, Synairgen shares were virtually unchanged
...Not a member? Join today
Joining ShareSoc helps to empower our collective voice in representing investors, but we also offer exclusive benefits:
Member events & Masterclasses
Regular newsletter
Member only on-line Forums / Q&As
Company data and Voting Guidance
Educational resources
Get involved in our activities
Already a member?
Log in to your account to access this content and all of your other ShareSoc membership benefits.